Lyme disease vaccine found cost-effective only for those at high risk

Lyme disease, a bacterial infection transmitted through deer tick bites, is rapidly emerging in the U.S. and currently affects about 15,000 people each year. But incidence varies widely according to region, with the highest rates in the Northeast and north central states. A group of researchers has looked at the cost-effectiveness of vaccination against Lyme disease and found it efficient only for people in high-risk areas who have a 1 percent or greater chance of getting it.